EUVIMEDEUVIMED entdecken
Crossref

Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis

Eon Kurumiya, Mayuu Iwata, Yoshitoshi Kasuya, Koichiro Tatsumi, Takuya Honda, Toshihiko Murayama, Hiroyuki Nakamura

European Journal of Pharmacology · 2024

DOI: 10.1016/j.ejphar.2024.176366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Eon Kurumiya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan. Hauptthemen laut MEDLINE: Myofibroblasts, Idiopathic Pulmonary Fibrosis, Pyrrolidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Japan Science and Technology Agency, Chiba University, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive chronic lung disease. Myofibroblasts play a critical role in fibrosis. These cells produce the extracellular matrix (ECM), which contributes to tissue regeneration; however, excess ECM production can cause fibrosis. Transforming growth factor-β (TGF-β)/Smad signaling induces ECM production by myofibroblasts; therefore, the inhibition of TGF-β/Smad signaling may be an effective strategy for IPF treatment. We recently reported that miglustat, an inhibitor of glucosylceramide synthase (GCS), ameliorates pulmonary fibrosis by inhibiting the nuclear translocation of Smad2/3. In the present study, we examined the anti-fibrotic effects of another GCS inhibitor, eliglustat, a clinically approved drug for treating Gaucher disease type 1, in myofibroblasts derived from patient with IPF (IPF-MyoFs). We found that eliglustat exerted anti-fibrotic effects independent of GCS inhibition, and inhibited TGF-β1-induced expression of α-smooth muscle actin, a marker of fibrosis, without suppressing the phosphorylation and nuclear translocation of Smad2/3. RNA sequencing analysis of eliglustat-treated human lung fibroblasts identified sterol regulatory element-binding protein 2 (SREBP2) activation. Transient overexpression of SREBP2 attenuated the TGF-β1-induced increase in the expression of Smad target genes in IPF-MyoFs, and SREBP2 knockdown nullified the inhibitory effect of eliglustat on TGF-β1-induced expression of α-SMA. These results suggested that eliglustat exerts its anti-fibrotic effects through SREBP2 activation. The findings of this study may contribute to the development of novel therapeutic strategies for IPF treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyofibroblastsIdiopathic Pulmonary FibrosisPyrrolidinesHumansTransforming Growth Factor beta1Cell DifferentiationLungFibroblastsTransforming Growth Factor beta

Stichwörter der Autor:innen

EliglustatIPFMyofibroblastsSREBP2SmadTGF-β

Substanzen

Transforming Growth Factor beta1eliglustatTransforming Growth Factor betaPyrrolidines

Autor:innen und Institutionen

  • Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.
  • Deprtment of Biomedical Science, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; Department of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba U…
  • Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
  • Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan. Electronic address: nakahiro@faculty.chiba-u.jp.

Förderung

  • Japan Science and Technology Agency
  • Chiba University
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kurumiya, E., Iwata, M., Kasuya, Y., Tatsumi, K., Honda, T., Murayama, T., & Nakamura, H. (2024). Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176366

Vancouver

Kurumiya E, Iwata M, Kasuya Y, Tatsumi K, Honda T, Murayama T, et al. Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176366

BibTeX
@article{Kurumiya2024,
  author = {Kurumiya, Eon and Iwata, Mayuu and Kasuya, Yoshitoshi and Tatsumi, Koichiro and Honda, Takuya and Murayama, Toshihiko and Nakamura, Hiroyuki},
  title = {Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis},
  journal = {European Journal of Pharmacology},
  year = {2024},
  doi = {10.1016/j.ejphar.2024.176366}
}
Kostenlos starten →